Sign In
NewsRadar

Press release centre

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.
   

Past Press Releases - KeyNeurotek AG

December 16, 2009
Breakthrough in treatment of traumatic brain Injury
KeyNeurotek Pharmaceuticals reports breakthrough in the treatment of patients with severe traumatic brain injury in a Phase IIa study. More

May 7, 2009
KeyNeurotek Pharmaceuticals opens new research facilities in Leipzig
KeyNeurotek Pharmaceuticals AG, a biotechnology company focused on the development and marketing of drugs against autoimmune diseases and degenerative disorders of the central nervous system (CNS), today announced the opening of new research facilities in Leipzig, Germany. More

April 7, 2009
KeyNeurotek Pharmaceuticals completes € 8.2 million ($ 10.8 million) series C financing round
KeyNeurotek Pharmaceuticals, a biotechnology company focused on the development and marketing of drugs against autoimmune diseases and degenerative disorders of the central nervous system, today announced the successful second closing of its Series C financing round. More

December 15, 2008
KeyNeurotek concludes patient recruitment in traumatic brain injury study
KeyNeurotek Pharmaceuticals concludes patient recruitment in a Phase IIa traumatic brain injury study with KN38-7271 on schedule More

September 22, 2008
KeyNeurotek Pharmaceuticals receives orphan drug designation of its lead compound
KeyNeurotek Pharmaceuticals receives orphan drug designation of its lead compound KN38-7271 for the treatment of moderate and severe closed traumatic brain injury from EMEA. More

July 10, 2008
KeyNeurotek Pharmaceuticals reports breakthrough discovery in Huntington´s Disease
Company elucidates molecular pathomechanism of Huntingtin mutation More

May 8, 2008
KeyNeurotek Pharmaceuticals reports positive phase I data of its cannabinoid receptor-agonist
KeyNeurotek Pharmaceuticals AG, a biotechnology company focused on the development and marketing of drugs against autoimmune diseases and degenerative disorders of the central nervous system (CNS), today announced positive results of a Phase I study with its cannabinoid receptor-agonist KN38-7271. More

Data


26,416
Tech investments
From our Online Data Service
17,054
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 30€3.6MSoftware development
Nov 29€3.6MBiopharmaceuticals
Nov 28N/ABiotechnology
Nov 28N/ABusiness applications
Nov 28€12.0MPublishing
Nov 28N/AeLearning
Nov 28€7.6MSensors

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.